Impact of a physician-supervised exercise-nutrition program with testosterone substitution in partial androgen-deficient middle-aged obese men
Ernst R Schwarz, Robert D Willix Jr, Ernst R Schwarz, Robert D Willix Jr
Abstract
Background: Partial androgen deficiency syndrome in the aging male is associated with signs of aging such as a development of abdominal obesity, sexual dysfunction, increase body fat, weight gain and the development of cardiac disease.
Objective: We assessed the outcome of a commercially available physician supervised nutrition and exercise program with concomitant testosterone replacement therapy in middle age obese men with partial androgen deficiency in order to reduce cardiac risks factors.
Methods: Fifty-six self referred men without diabetes mellitus, hypertension, or cardiovascular disease (ages 52.3 ± 7.8 years) were randomly selected from a large cohort. Baseline weight, body fat composition, fasting glucose, hemoglobin A1c and fasting lipid levels, as well as free and total testosterone levels were assessed. All patients were assessed and followed 6-18 months after initiation of the program. The program consisted of a low glycemic load balanced nutrition diet, a recommended structured daily exercise program of 30-60 minutes, as well as once to twice weekly intramuscular testosterone injections (113.0 ± 27.8 mg).
Results: At follow up, weight was reduced from 233.9 ± 30.0 pounds (lbs) to 221.3 ± 25.1 lbs (P < 0.001), BMI was reduced from 33.2 ± 3.3 kg/m(2) to 31.3 ± 2.8 kg/m(2) (P < 0.0001). Total body fat was 27.1% ± 5.2% vs. 34.3% ± 5.7% at baseline (P < 0.0001). Fasting glucose was reduced from 95.3 ± 14.4 mg/dL to 87.5 ± 12.6 mg/dL (P < 0.0001). Total cholesterol was reduced from 195.4 ± 33.0 mg/dL to 172.7 ± 35.0 mg/dL (P < 0.005). No clinically significant adverse events were recorded.
Conclusions: Testosterone replacement therapy in middle aged obese men with partial androgen deficiency appeared safe and might have promoted the effects of a weight reduction diet and daily exercise program as long as an adequate physician supervision and follow up was granted. The combination therapy significantly reduced coronary risk factors such as glucose intolerance and hyperlipidemia.
Keywords: aging; androgen deficiency; heart disease; testosterone.
References
- Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest. 1999;22:110–116.
- Kravchenko AIa, Provotorov VM. Age-related androgen deficiency in men with ischemic heart disease. Adv Gerontol. 2008;21:311–313.
- Hofer HG. Men in a critical age: Kurt Mendel and the controversy over the male climacterium. Urologe A. 2011;50:839–845.
- Nau JY. Normality of the libido (andropause) Rev Med Suisse. 2010;6:1518–1519.
- Delev DP, Kostadinova II, Kostadinov ID, et al. Physiological and clinical characteristics of andropause. Folia Med. 2009;51:15–22.
- Schwarz ER, Phan A, Willix RD. Andropause and the development of cardiovascular disease presentation―more than an epi-phenomenon. J Geriatr Cardiol. 2011;8:35–43.
- Pines A. Male menopause: is it a real clinical syndrome? Climacteric. 2011;14:15–17.
- Arnheim K. Testosterone deficiency syndrome. Imaginary disease or true complaint picture? MMW Fortschr Med. 2010;152:16.
- Holm AC, Fredrikson MG. More than half of the men in a Swedish population of men aged 55, 65 and 75 believe in ‘a male climacteric’. Aging Male. 2011;14:16–20.
- Yassin AA, Saad F, Gooren LJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia. 2008;40:259–264.
- Wehr E, Pilz S, Boehm BO, et al. Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail. 2011;13:482–488.
- Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96:1821–1825.
- Schwarcz MD, Frishman WH. Testosterone and coronary artery disease. Cardiol Rev. 2010;18:251–257.
- Gobal F, Deshmukh A, Shah S, et al. Triad of metabolic syndrome, chronic kidney disease, and coronary heart disease with a focus on microalbuminuria death by overeating. J Am Coll Cardiol. 2011;57:2303–2308.
- Aoki J, Uchino K. Treatment of risk factors to prevent stroke. Neurotherapeutics. 2011;8:463–474.
- Cortez-Dias N, Martins S, Belo A, et al. Comparison of definitions of metabolic syndrome in relation to risk for coronary artery disease and stroke. Rev Port Cardiol. 2011;30:139–169.
- Bischoff SC, Damms-Machado A, Betz C, et al. Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life-a prospective study. Int J Obes (Lond) 2011 in press.
- Owen K, Pettman T, Haas M, et al. Individual preferences for diet and exercise programmes: changes over a lifestyle intervention and their link with outcomes. Public Health Nutr. 2010;13:245–252.
- Wickham EP, Stern M, Evans RK, et al. Prevalence of the metabolic syndrome among obese adolescents enrolled in a multidisciplinary weight management program: clinical correlates and response to treatment. Metab Syndr Relat Disord. 2009;7:179–186.
- Musto A, Jacobs K, Nash M, et al. The effects of an incremental approach to 10,000 steps/day on metabolic syndrome components in sedentary overweight women. J Phys Act Health. 2010;7:737–745.
- MKim MK, Tanaka K, Kim MJ, et al. Exercise training- induced changes in heart rate recovery in obese men with metabolic syndrome. Metab Syndr Relat Disord. 2009;7:469–476.
- Joseph LJ, Prigeon RL, Blumenthal JB, et al. Weight loss and low-intensity exercise for the treatment of metabolic syndrome in obese postmenopausal women. J Gerontol A Biol Sci Med Sci. 2011;66:1022–1029.
- Kreider RB, Rasmussen C, Kerksick CM, et al. A carbohydrate-restricted diet during resistance training promotes more favorable changes in body composition and markers of health in obese women with and without insulin resistance. Phys Sportsmed. 2011;39:27–40.
- Kong W, Langlois MF, Kamga-Ngandé C, et al. Predictors of success to weight-loss intervention program in individuals at high risk for type 2 diabetes. Diabetes Res Clin Pract. 2010;90:147–153.
- Theodoraki A, Bouloux PM. Testosterone therapy in men. Menopause Int. 2009;15:87–92.
- Gasser RW. Androgen therapy from the viewpoint of the internal medicine physician. Wien Med Wochenschr. 2001;151:444–447.
Source: PubMed